Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLPH vs BIOA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLPH Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

TLPH Overall Winner 6-Pillar Tally: TLPH 3 – 2 BIOA (1 Tie) Matrix Metrics: TLPH 6 – 3 BIOA

As of Nov 16, 2026, Talphera, Inc. (TLPH) is the stronger overall head-to-head candidate over BioAge Labs, Inc. (BIOA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas BIOA carries 36.0/100 (SELL) at $5.17 (N/M Forward P/E, -1401.8% operating margin).

  • Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both TLPH (37.1/100 SELL) and BIOA (36.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile BIOA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLPH vs BIOA
TLPH NASDAQ Head-to-Head Winner
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10
BIOA NASDAQ
BioAge Labs, Inc. Common Stock
Pharmaceutical Preparations
$5.17
-6.85% 1D
Market Cap $259.6M
TTM Revenue $8.6M
Forward P/E N/M
Beta / 30D Vol 2.21β · 83% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 49.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 38
RSI-14: 37.6 · SMA20: $5.61 · SMA50: $6.51

6-Pillar Scorecard Institutional Category Breakdown (TLPH 3 – 2 BIOA)

Columns: Metric · TLPH · BIOA
1. Valuation Multiples TLPH
Forward P/E 1.0x N/M
Trailing P/E 1.0x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 24.4x
2. Growth & Scale TLPH
Revenue Growth (YoY) +0.0% -85.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1,000 $8.6M
Market Cap $53.7M $259.6M
3. Profitability & Quality BIOA
Gross Margin N/A N/A
Operating Margin -1474700.0% -1401.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -143.4% -34.6%
4. Balance Sheet & Cash Flow BIOA
Cash Generation (TTM) -$15M EBITDA -$103M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.28 Book/Sh · -143.4% ROE $50M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TLPH
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 118.4% (100th %ile) 112.7% (24th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLPH (6) vs BIOA (3)
Institutional Metric TLPH BIOA Criterion Row Edge
Market Capitalization
Scale
$53.7M $259.6M Larger Scale BIOA
Trailing P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Forward P/E Ratio
Valuation
1.0x N/M Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% -85.5% Higher Growth TLPH
Operating Margin (TTM)
Profitability
-1474700.0% -1401.8% Higher Margin BIOA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-143.4% -34.6% Higher ROE BIOA
52-Week Range Position
Momentum
20% ($1–$2) 2% ($5–$26) Stronger Trend TLPH
Beta / 30D Volatility
Risk Regime
1.11β · 58% Vol 2.21β · 83% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 36.0 / 100 (SELL) Higher Composite TLPH
Trailing 12M Revenue (USD)
Operating Scale
$1,000 $8.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 24.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) -$103M ($50M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIOA +27.11 pp
TLPH: -20.29% · BIOA: +6.82%
3M Horizon TLPH +21.72 pp
TLPH: -28.85% · BIOA: -50.57%
6M Horizon TLPH +74.28 pp
TLPH: +7.98% · BIOA: -66.3%
1Y Horizon TLPH +15.02 pp
TLPH: -18.01% · BIOA: -33.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs BIOA. Trailing 12-month operating profitability (TLPH -1474700.0% vs BIOA -1401.8%) and valuation multiples (TLPH 1.0x vs BIOA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x
BIOA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$8.6M
Gross MarginN/A
Op. Margin-1401.8%
ROE / Fwd P/E-34.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BIOA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 112.7%
IV Percentile 24th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BIOA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BIOA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $259.6M market capitalization and -1401.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TLPH vs BIOA Key Questions & Quantitative Answers

As of Nov 16, 2026, Talphera, Inc. (TLPH) is the stronger overall head-to-head candidate over BioAge Labs, Inc. (BIOA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). TLPH carries a Unified Composite Score of 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin), whereas BIOA carries 36.0/100 (SELL) at $5.17 (N/M Forward P/E, -1401.8% operating margin). Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both TLPH (37.1/100 SELL) and BIOA (36.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: TLPH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile BIOA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLPH leads the Growth & Scale pillar: TLPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin), compared with BIOA at -85.5% YoY revenue growth and +0.0% YoY earnings growth on $8.6M TTM revenue (N/A gross margin, -1401.8% operating margin). On trailing 12-month operating scale, TLPH generates $1,000 in USD-normalized revenue versus $8.6M for BIOA. In operating R&D and SG&A reinvestment, TLPH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BIOA.

TLPH screens cheaper on headline valuation multiples. TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas BIOA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 24.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLPH (-143.4% ROE) versus BIOA (-34.6% ROE) capital efficiency.

In options market volatility and institutional positioning, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk). By comparison, BIOA carries 112.7% implied volatility (24th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.21β · 83% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.